FLASH - Carmat - Acheter, Opinion inchangée - Obj. 28,20€
Carmat fait le point sur son activité et annonce ses premières guidances de CA pour 2023. A ce stade, la société anticipe un CA de 10 à 13 M€ sur 2023 en lien avec la reconstitution progressive des stocks de prothèses. La société cible un retour à son rythme de croisière de 20 cœurs par mois d'ici octobre 2023 et entend atteindre une capacité de 500 cœurs par an dès 2024. Nous ajustons notre objectif de cours à 28.2€.Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.